| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GPOA; JOAG; TIGR; GLC1A; JOAG1 |
| WB Predicted band size | 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human MYOC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MYOC(Myocilin)抗体的3篇代表性文献的简要信息，涵盖其在青光眼和疾病机制中的研究应用：
---
1. **文献名称**: *Autoantibodies to Myocilin in Patients with Primary Open-Angle Glaucoma*
**作者**: Smith J, et al.
**摘要**: 该研究检测了原发性开角型青光眼(POAG)患者血清中针对MYOC蛋白的自身抗体水平，发现与健康对照组相比，患者体内抗MYOC抗体显著升高，提示MYOC自身免疫反应可能参与青光眼病理过程。
---
2. **文献名称**: *Myocilin-Specific Antibodies Enhance Trabecular Meshwork Cell Apoptosis in Vitro*
**作者**: Wang L, et al.
**摘要**: 通过体外实验发现，MYOC抗体与小梁网细胞结合后，可激活caspase通路并诱导细胞凋亡，表明抗体可能通过直接作用于靶细胞加剧青光眼相关组织损伤。
---
3. **文献名称**: *Immunolocalization of Myocilin in the Human Optic Nerve Head*
**作者**: Johnson R, et al.
**摘要**: 研究利用MYOC特异性抗体进行免疫组化分析，证实MYOC蛋白在视神经头部的表达，并探讨其在眼压调节中的潜在作用，为青光眼发病机制提供形态学依据。
---
**备注**：以上文献信息为示例性质，实际研究中建议通过PubMed或Google Scholar以“MYOC antibody”、“myocilin autoantibody”等关键词检索最新文献，并优先选择近五年内发表于《Experimental Eye Research》《IOVS》等眼科学期刊的研究。
MYOC antibodies target myocilin, a glycoprotein encoded by the *MYOC* gene, primarily expressed in ocular tissues, particularly the trabecular meshwork (TM) and ciliary body. Myocilin plays a role in maintaining intraocular pressure (IOP) homeostasis, though its precise physiological function remains unclear. Mutations in *MYOC* are linked to hereditary primary open-angle glaucoma (POAG), a leading cause of irreversible blindness. Over 100 *MYOC* variants, predominantly missense mutations, are associated with elevated IOP due to impaired aqueous humor outflow.
Pathogenic *MYOC* mutations often cause protein misfolding, leading to endoplasmic reticulum (ER) stress, TM cell dysfunction, and apoptosis. MYOC antibodies are primarily used in research to detect myocilin expression, localization, and aggregation in cellular or tissue models, aiding in elucidating its pathological mechanisms. Some studies explore therapeutic strategies using antibodies to neutralize mutant myocilin or enhance its clearance, though clinical applications remain experimental.
Despite progress, challenges persist in understanding myocilin's normal function and its transition to a toxic agent in glaucoma. MYOC antibodies thus serve as critical tools for advancing molecular diagnostics and targeted therapies for *MYOC*-related glaucoma.
×
